$XBI $138.5 +2.3%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA +0.1% Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency. source
$OYST -0.7% Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants. source
$ VALN +2.3% Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate. source
Pipeline Updates
$SCPH +17.0% scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®. source
$KRYS +5.5% Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis. source
$PBYI +2.3% FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer. source
$CTXR -25.3% Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned. source
$HRTX -2.4% Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEFâ„¢ for the Management of Postoperative Pain for up to 72 Hours. source
$IMAB +0.6% I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio. source
$CLSN -1.6% Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer. source
$RFL +6.4% Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML). source
$ALRN +4.8% Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). source
$ACHL +1.4% Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer. source
$EYPT -0.4% EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association. source
$CNCE -3.8% Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit. source
$MCRB -5.2% Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement. source
$DTIL +1.1% Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma. source
$NGM +6.6% NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases. source
$IMUX +5.5% Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis. source
$ARQT -2.9% Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo. source
$ORTX -2.3% & PHAR +2.0% Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema. source
$JAZZ +2.0% Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylazeâ„¢ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. source
$SLS -16.0% On 6/30 SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer. source
Financial Updates
$AFMD -11.7% Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress. source
$BSGM -11.7% BioSig Announces Proposed Public Offering of Common Stock. source
$KYMR +15.6% Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock. source
$ALGS -17.3% Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock. source
$SPRO +17.4% Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206. source
Posted by FS